REFERENCES
- Huang, L., S. Chao, and C. Hu. 2020. Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science 27 (1):18. doi:https://doi.org/10.1186/s12929-019-0609-7.
- Kim, H. J., and B. Jeon. 2019. Decision under risk: Argument against early deep brain stimulation in Parkinson’s disease. Parkinsonism & Related Disorders 69:7–10. doi:https://doi.org/10.1016/j.parkreldis.2019.10.008.
- Leoutsakos, J. S., H. Yan, W. S. Anderson, W. F. Asaad, G. Baltuch, A. Burke, M. M. Chakravarty, K. E. Drake, K. D. Foote, L. Fosdick, et al. 2018. Deep brain stimulation targeting the fornix for mild Alzheimer dementia (the ADvance Trial): A two year follow-up including results of delayed activation. Journal of Alzheimer's Disease 64 (2):597–606. doi:https://doi.org/10.3233/JAD-180121.
- McKeown, A., G. S. Malhi, and I. Singh. 2021. Ethics of early intervention in Alzheimer’s disease. AJOB Neuroscience 12 (4):212–223. doi:https://doi.org/10.1080/21507740.2021.1896595.
- Mestre, T. A., A. J. Espay, C. Marras, M. H. Eckman, P. Pollak, and A. E. Lang. 2014. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: Early is not always better. Movement Disorders 29 (14):1751–6. doi:https://doi.org/10.1002/mds.26024.
- Okonkwo, O. C., H. R. Griffith, J. N. Copeland, K. Belue, S. Lanza, E. Y. Zamrini, L. E. Harrell, J. C. Brockington, D. Clark, R. Raman, et al. 2008. Medical decision-making capacity in mild cognitive impairment: A 3-year longitudinal study. Neurology 71 (19):1474–80. doi:https://doi.org/10.1212/01.wnl.0000334301.32358.48.
- Okun, M. S. 2012. Deep-brain stimulation for Parkinson's disease. New England Journal of Medicine 367 (16):1529–38. doi:https://doi.org/10.1056/NEJMct1208070.
- Schuepbach, W. M., J. Rau, K. Knudsen, J. Volkmann, P. Krack, L. Timmermann, T. D. Hälbig, H. Hesekamp, S. M. Navarro, N. Meier, et al. 2013. Neurostimulation for Parkinson's disease with early motor complications. New England Journal of Medicine 368 (7):610–22. doi:https://doi.org/10.1056/NEJMoa1205158.
- Schüpbach, W. M., J. Rau, J. L. Houeto, P. Krack, A. Schnitzler, C. Schade-Brittinger, L. Timmermann, and G. Deuschl. 2014. Myths and facts about the EARLYSTIM study. Movement Disorders 29 (14):1742–50. doi:https://doi.org/10.1002/mds.26080.
- Startin, C. M., S. Hamburg, R. Hithersay, T. Al-Janabi, K. Y. Mok, J. Hardy, and A. Strydom. 2019. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer’s & Dementia 15 (2):245–57. doi:https://doi.org/10.1016/j.jalz.2018.08.009.
- Stilgoe, J., R. Owen, and P. Macnaghten. 2013. Developing a framework for responsible innovation. Research Policy 42 (9):1568–80. doi:https://doi.org/10.1016/j.respol.2013.05.008.
- Viaña, J. N. M., M. Bittlinger, and F. Gilbert. 2017. Ethical considerations for deep brain stimulation trials in patients with early-onset Alzheimer’s disease. Journal of Alzheimer's Disease 58 (2):289–301. doi:https://doi.org/10.3233/JAD-161073.
- Viaña, J. N. M., A. Carter, and F. Gilbert. 2018. Of meatballs and invasive neurotechnological trials: Additional considerations for complex clinical decisions. AJOB Neuroscience 9 (2):100–4. doi:https://doi.org/10.1080/21507740.2018.1460417.
- Viaña, J. N. M., and F. Gilbert. 2019. Deep brain stimulation for people with Alzheimer's disease: Anticipating potential effects on the tripartite self. Dementia 18 (7–8):2836–55. doi:https://doi.org/10.1177/1471301218761147.
- Viaña, J. N., S. Raman, and J. Leach. 2020. Responsible innovation for and from ethical integration. The American Journal of Bioethics 20 (4):94–7. doi:https://doi.org/10.1080/15265161.2020.1730496.
- Viaña, J. N., S. Raman, and M. Barber. 2021. From paternalism to engagement: Bioethics needs a paradigm shift to address racial injustice during COVID-19. The American Journal of Bioethics 21 (2):96–8. doi:https://doi.org/10.1080/15265161.2020.1861375.
- Viaña, J. N. M., J. C. Vickers, M. J. Cook, and F. Gilbert. 2017. Currents of memory: Recent progress, translational challenges, and ethical considerations in fornix deep brain stimulation trials for Alzheimer's disease. Neurobiology of Aging 56:202–10. doi:https://doi.org/10.1016/j.neurobiolaging.2017.03.001.
- Zetterberg, H., and B. B. Bendlin. 2021. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. Molecular Psychiatry 26 (1):296–308. doi:https://doi.org/10.1038/s41380-020-0721-9.